Pilot trial points to immune-targeted therapy for hard-to-treat depression
A small randomized trial suggests the anti-inflammatory drug tocilizumab may ease symptoms in people with moderate-to-severe depression who have not improved on standard antidepressants, adding fresh weight to the idea a
- A 30-person pilot trial tested tocilizumab in moderate-to-severe depression that had not responded to standard antidepressants.
- Compared with placebo, the anti-inflammatory drug appeared to reduce depression symptoms and improve fatigue, anxiety, and quality of life.

